ArticleJournal of blood medicine2026
Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.
Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved long-term survival of patients with CD56-positive acute myeloid leukemia (AML). Patients and Methods: According to predefined inclusion and exclusion criteria, 188 patients with non-M3 AML, newly diagnosed between March 1, 2017, and May 1, 2024, were enrolled in this retrospective analysis. Patients were categorized according to CD56-expression status, ELN 2022 risk stratification, and treatment choices. Clinical characteristics, remission rates, disease-free survival (DFS), overall survival (OS), and cumulative incidence of relapse (CIR) were compared between patients with CD56-positive and CD56-negative diseases. Prognostic factors were analyzed, and the prognostic impact of CD56-expression was further evaluated within transplanted and non-transplanted subgroups. Results: The median follow-up time was 1102 days (interquartile range, 632-1942 days). In the CD56-positive subgroup, patients with non-transplanted had lower 3-year OS than those with allo-HSCT (22.8% vs 73.1%; Conclusion: Allo-HSCT might improve long-term survival in patients with CD56-positive AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.